UBS Group’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.65M | Buy |
48,911
+950
| +2% | +$53K | ﹤0.01% | 4712 |
|
|
2025
Q4 | $2.69M | Buy |
47,961
+11,948
| +33% | +$619K | ﹤0.01% | 4681 |
|
|
2025
Q3 | $1.73M | Buy |
36,013
+4,965
| +16% | +$222K | ﹤0.01% | 5094 |
|
|
2025
Q2 | $1.26M | Sell |
31,048
-12,230
| -28% | -$492K | ﹤0.01% | 5238 |
|
|
2025
Q1 | $1.9M | Sell |
43,278
-4,298
| -9% | -$190K | ﹤0.01% | 4746 |
|
|
2024
Q4 | $2.05M | Buy |
47,576
+7,432
| +19% | +$338K | ﹤0.01% | 4693 |
|
|
2024
Q3 | $1.78M | Buy |
40,144
+1,345
| +3% | +$57.6K | ﹤0.01% | 4118 |
|
|
2024
Q2 | $1.54M | Sell |
38,799
-2,386
| -6% | -$96.7K | ﹤0.01% | 4022 |
|
|
2024
Q1 | $1.78M | Sell |
41,185
-668
| -2% | -$28.8K | ﹤0.01% | 4064 |
|
|
2023
Q4 | $1.74M | Buy |
41,853
+18,857
| +82% | +$715K | ﹤0.01% | 3972 |
|
|
2023
Q3 | $914K | Sell |
22,996
-877
| -4% | -$37.1K | ﹤0.01% | 4156 |
|
|
2023
Q2 | $979K | Sell |
23,873
-687
| -3% | -$28.4K | ﹤0.01% | 4272 |
|
|
2023
Q1 | $1.01M | Sell |
24,560
-498,422
| -95% | -$20.9M | ﹤0.01% | 4089 |
|
|
2022
Q4 | $21.4M | Buy |
522,982
+120,085
| +30% | +$5M | 0.01% | 1356 |
|
|
2022
Q3 | $16.2M | Sell |
402,897
-33,352
| -8% | -$1.43M | 0.01% | 1419 |
|
|
2022
Q2 | $18.3M | Buy |
436,249
+405,089
| +1,300% | +$17M | 0.01% | 1372 |
|
|
2022
Q1 | $1.41M | Buy |
31,160
+2,438
| +8% | +$107K | ﹤0.01% | 3766 |
|
|
2021
Q4 | $1.33M | Buy |
28,722
+618
| +2% | +$29.3K | ﹤0.01% | 4138 |
|
|
2021
Q3 | $1.33M | Sell |
28,104
-741
| -3% | -$36.8K | ﹤0.01% | 3933 |
|
|
2021
Q2 | $1.49M | Sell |
28,845
-765
| -3% | -$38.4K | ﹤0.01% | 3838 |
|
|
2021
Q1 | $1.49M | Sell |
29,610
-312
| -1% | -$16.6K | ﹤0.01% | 3854 |
|
|
2020
Q4 | $1.56M | Sell |
29,922
-1,150
| -4% | -$55K | ﹤0.01% | 3631 |
|
|
2020
Q3 | $1.35M | Buy |
31,072
+1,874
| +6% | +$82.1K | ﹤0.01% | 3416 |
|
|
2020
Q2 | $1.25M | Sell |
29,198
-9
| -0% | -$372 | ﹤0.01% | 3308 |
|
|
2020
Q1 | $1.05M | Sell |
29,207
-2,609
| -8% | -$111K | ﹤0.01% | 3300 |
|
|
2019
Q4 | $1.45M | Buy |
31,816
+824
| +3% | +$32.7K | ﹤0.01% | 3864 |
|
|
2019
Q3 | $1.1M | Sell |
30,992
-2,862
| -8% | -$106K | ﹤0.01% | 3882 |
|
|
2019
Q2 | $1.35M | Sell |
33,854
-380
| -1% | -$14.9K | ﹤0.01% | 3493 |
|
|
2019
Q1 | $1.42M | Sell |
34,234
-16,031
| -32% | -$652K | ﹤0.01% | 3293 |
|
|
2018
Q4 | $1.84M | Sell |
50,265
-87,452
| -64% | -$3.73M | ﹤0.01% | 3123 |
|
|
2018
Q3 | $6.69M | Buy |
137,717
+64,386
| +88% | +$3.05M | ﹤0.01% | 2102 |
|
|
2018
Q2 | $3.15M | Sell |
73,331
-6,810
| -8% | -$286K | ﹤0.01% | 2749 |
|
|
2018
Q1 | $3.36M | Sell |
80,141
-51,626
| -39% | -$2.25M | ﹤0.01% | 2681 |
|
|
2017
Q4 | $5.73M | Sell |
131,767
-17,763
| -12% | -$755K | ﹤0.01% | 2223 |
|
|
2017
Q3 | $6.36M | Sell |
149,530
-93,821
| -39% | -$3.98M | ﹤0.01% | 1992 |
|
|
2017
Q2 | $10.5M | Sell |
243,351
-197,335
| -45% | -$8.32M | 0.01% | 1499 |
|
|
2017
Q1 | $18.4M | Sell |
440,686
-193,525
| -31% | -$7.89M | 0.01% | 1081 |
|
|
2016
Q4 | $24.8M | Buy |
634,211
+197,181
| +45% | +$8.02M | 0.01% | 903 |
|
|
2016
Q3 | $19.3M | Buy |
437,030
+213
| +0% | +$9.67K | 0.01% | 1005 |
|
|
2016
Q2 | $18.3M | Sell |
436,817
-28,021
| -6% | -$1.19M | 0.01% | 988 |
|
|
2016
Q1 | $18.7M | Sell |
464,838
-88,540
| -16% | -$3.75M | 0.01% | 929 |
|
|
2015
Q4 | $28.3M | Buy |
553,378
+99,675
| +22% | +$5.08M | 0.02% | 766 |
|
|
2015
Q3 | $21.3M | Buy |
453,703
+265,565
| +141% | +$16M | 0.02% | 866 |
|
|
2015
Q2 | $11.7M | Sell |
188,138
-299,058
| -61% | -$18.6M | 0.01% | 1349 |
|
|
2015
Q1 | $30.1M | Sell |
487,196
-207,674
| -30% | -$12.3M | 0.02% | 727 |
|
|
2014
Q4 | $37.5M | Buy |
+694,870
| New | +$38M | 0.03% | 661 |
|
Other funds holding XPH
KWM
FCBT
UBS Group's XPH Position: Q1 2026 in Review
UBS Group increased its State Street SPDR S&P Pharmaceuticals ETF (XPH) stake by 2% in Q1 2026, buying an estimated $53K and bringing the position to 48,911 shares worth $2.65M. The position accounts for ﹤0.01% of the portfolio, ranked #4712.
UBS Group first reported a position in XPH in Q4 2014 and has held it in 46 quarters since. The position peaked at $37.5M in Q4 2014. 82 funds tracked by Wall St. Rank hold XPH as of Q1 2026.
- UBS Group held 48,911 shares of State Street SPDR S&P Pharmaceuticals ETF worth $2.65M as of Q1 2026.
- UBS Group bought 950 State Street SPDR S&P Pharmaceuticals ETF shares in Q1 2026, an estimated $53K.
- State Street SPDR S&P Pharmaceuticals ETF made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #4712 holding.
- UBS Group first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q4 2014 and has held it in 46 quarters since.
- UBS Group's State Street SPDR S&P Pharmaceuticals ETF position peaked at $37.5M in Q4 2014.
- 82 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.